Dutch biotech RougeTx raised $58 million in a Series A to advance an oral small-molecule program for hereditary hemorrhagic telangiectasia (HHT). The company’s strategy centers on reattaching pericytes to stabilize blood vessels, a mechanism intended to reduce disease complications. The financing highlights investor appetite for mechanism-led rare-disease assets with an oral format that could simplify long-term management relative to existing approaches. RougeTx’s next milestones will be driven by preclinical-to-clinical translation, including dose selection and target engagement readouts in HHT populations.